On Monday, Bayer AG (OTC:BAYRY) submitted an application to the European Medicines Agency (EMA) for the oral androgen receptor inhibitor (ARi) darolutamide. Bayer is seeking approval for the use of darolutamide in combination with androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The compound is already approved in mHSPC, under the brand name Nubeqa, in combination with ADT and docetaxel in over 80 markets. Also Read: Roivant Sciences Unveils New ‘Vant’ Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer. The compound is als…